Background
Charcot-Marie-Tooth disease-5 (CMTX5, MIM 311070 [
1,
2]), Arts syndrome (MIM 301835 [
3,
4]) and X-linked nonsyndromic sensorineural deafness (DFN2; MIM 304500 [
5]) present three clinically distinct but genetically allelic disorders, caused by reduced phosphoribosylpyrophosphate synthetase 1 (PRS1) activity due to
PRPS1 mutations [
6]. Only three families with CMTX5 and two families Arts syndrome, respectively, have been reported worldwide so far [
1,
3,
7]. Thus, evidence is still rare whether these two disorders are separate entities, or rather clusters on a phenotypic continuum of
PRPS1-related disease. In addition, knowledge about intrafamilial variability and phenotypic manifestations in female carriers is limited.
Here, we report a family with a novel PRPS1 missense mutation providing several new insights in PRS-I -hypoactivity disease. First, features of CMTX5 and Arts syndrome features can overlap within individuals, indicating an intraindividual continuum of these two disorders. Second, CMTX5/Arts and (prelingual, severe) DFN2 can present within one and the same family, revealing an intrafamilial continuum of these disorders. Third, the respective phenotypic presentation along the continuous spectrum of PRPS1-related disease seems to be determined by the exact PRPS1 mutation and the degree of residual PRS-I enzyme activity, the latter being largely influenced by the degree of skewed X-inactivation.
Methods
The index patient, his sister and his mother were investigated by (i) detailed clinical examination by a specialist in rare neurogenetic disorders, (ii) routine laboratory serum tests including uric acid analysis, (iii) enzymatic analyses of PRS-I activity in erythrocytes (for methodological details, see Additional file
1), and (iv)
PRPS1 DNA sequence analysis (for methodological details, see Additional file
2). Additionally, the index patient and his sister were assessed by (v) nerve conduction studies, (vi) ophthalmological funduscopy, and (vii) routine brain magnetic resonance imaging (MRI).
The frequency of the identified
PRPS1 variant was determined in more than 4,250 X-chromosomes of European control individuals with unrelated phenotypes analyzed by exome sequencing (for methodological details, see [
8]). In addition, the frequency of the change was assessed in the exome variant server (EVS) of the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (Seattle, WA, USA; URL: evs.gs.washington.edu/EVS/) with the corresponding nucleotide positions being analyzed in >8,000 European and >4,000 African American alleles, and in the Database of Single Nucleotide Polymorphisms (dbSNP; Bethesda: National Center for Biotechnology Information, National Library of Medicine [dbSNP Build ID: 138]; available from:
http://www.ncbi.nlm.nih.gov/SNP/).
In-silico predictions of the pathogenicity of genetic variants were performed using PolyPhen-2 [
9], SIFT [
10] and MutationTaster [
11]. The effect of the amino acid change on the structure of
PRPS1 was predicted using the crystal structure of human
PRPS1 from [
12] (PDB entry 2H06;
http://www.pdb.org/) as described before [
4]. X-inactivation patterns in female
PRPS1 mutation carriers were tested by using the highly polymorphic (CAG)n region of the human androgen receptor gene (HUMARA locus) after methylation-sensitive digestion with HpaII, as described previously [
13]. This study was carried out in compliance with the Helsinki Declaration, and approved by the Institutional Review Board of the University of Tübingen, reference number 598/20118O1.
Consent
Written informed consent was obtained from the patients for the publication of this report and any accompanying images.
Discussion
Here we report a family with a novel
PRPS1 mutation which provides new insights in
PRPS1-related disease. The index patient (subject II-2) showed an overlapping phenotype combining features of both CMTX5 and (mild, relatively late-onset) Arts syndrome. Prelingual hearing loss, optic atrophy with onset in the teens and severe sensorimotor neuropathy are part of the classical CMTX5 trias [
2]. However, recurrent infections in childhood leading to acute deteriorations of slowly progressive muscle weakness, severe ataxia leading to walker-dependency, mild to moderate mental and behavioural deficits, and institutionalization in homes for physically and mentally handicapped are all features not reported in previous CMTX5 subjects, but known from subjects with Arts syndrome (though usually in a more severe early-onset form) [
3,
17]. This shows that CMTX5 and Arts syndrome can overlap within one and the same individual, thus indicating a continuous spectrum of PRS1- hypoactivity disease. This finding corroborates and extends the recent observation from one individual with PRS-I superactivity who showed not only signs of PRS-I superactivity syndrome, but also of Arts syndrome [
18]. Taken together, these findings indicate that both PRS1 superactivity and PRS-I hypoactivity disorders form a continuous gradual spectrum of disease.
The notion of a continuous disease spectrum of PRS1-hypoactivity disorders is further supported by our observation that a CMTX5/Arts overlapping phenotype can co-occur within the same family as a DFN2 phenotype (subject II-1), demonstrating an intrafamilial continuum of these three clusters of PRS-I hypoactivity diseases. So far, CMTX5, Arts syndrome and DFN2 were only reported in different families, not within the same family [
6]. An earlier report already indicated that some subjects can present with an only incomplete presentation of a PRPS1 disease cluster (e.g. absence of optic atrophy in CMTX5 subjects [
7]). Taken together, these findings suggest a continuous spectrum of
PRPS1 disease features, where hearing loss, peripheral neuropathy, optic atrophy, ataxia, cognitive deficits and recurrent infections are central, yet variable phenotypic features. Along this spectrum, the established
PRPS1 disease clusters are not separate entities, but endophenotypes on a phenotypic continuum.
Female carriers in families with Arts syndrome were known to sometimes exhibit some hearing impairment later in life (age >20 years) combined with ataxia and neuropathy [
3,
19]; yet prelingual hearing loss starting at birth - as observed in subject II-1 - has not yet been described in these families. Female carriers in families with CMTX5 are noted to be asymptomatic [
1]. Our findings indicate that these current notions and corresponding counselling recommendations of female carriers in families with CMTX5 [
1] or Arts syndrome [
3] should be revised: female carriers in families with these phenotypic clusters can show symptoms already very early in life, leading to substantial impairment in everyday social life.
How might this intrafamilial continuum of
PRPS1 disease clusters be explained? Our results indicate that the respective phenotypic presentation seems to be determined by (1.) the exact
PRPS1 mutation (in males) and (2.) the residual enzyme activity, which in turn is largely influenced by the degree of skewed X-inactivation (in females). The predicted structural effects of the p.Gln277Pro mutation fall in between those of the CMTX5 and Arts syndrome
PRPS1 mutations (Table
2), thus explaining the CMTX/Arts syndrome overlapping phenotype in the male index patient II-2. PRS-I enzyme activity was not detectable in this male subject with the most complex and severe phenotype, while it was moderately reduced in his sister II-1 with a nonsyndromic hearing loss phenotype (DFN2), and normal in his unaffected mother I-1. (Figure
1B). The lack of detectable PRS-I activity in subject II-2 might explain why his phenotypic presentation included components of the Arts cluster, as absence of PRS-I activity has already been reported for patients with a pure Arts phenotype [
4]. The residual PRS-I activity in the female carriers (I-1; II-1) might be explained by compensation through the second (intact) X chromosome. PRS-I activity was lower in subject II-1 than in subject I-1, most likely due to severely skewed X-chromosome inactivation which was observed in this subject. Alternatively, tissue-specific control of other genetic and epigenetic mechanisms might explain the differences in PRS1 activity between I-1 and II-1, e.g. the regulation of
PRPS1 by microRNA-376 [
17] and difference in expression levels and function of the other three PRS isoforms [
6]. Our finding of a clinico-enzymatic correlation between enzymatic activity and disease severity indicates that PRS-I activity may serve as a blood biomarker for
PRPS1 disease and may help to corroborate pathogenicity of novel
PRPS1 variants of unknown significance. It also suggests that it might serve as an interesting readout and surrogate parameter for treatment efficacy.
So far, cerebral MRI abnormalities have been observed neither in CMTX5 nor in Arts syndrome [
3], yet such abnormalities are likely given the wide range of clinical central nervous abnormalities in
PRPS1-disorders, in particular in Arts syndrome. Here we show that mild signs of cerebellar and parietal atrophy can be seen in both subject II-2 and subject II-1, thus providing first evidence for structural central nervous system damage in
PRPS1- disease. As atrophy is very mild, it might have been present also in previous
PRPS1 subjects, yet not been recognized. Our finding of a subject with adolescent-onset ataxia with neuropathy, optic atrophy, hearing loss, and mild atrophy of the cerebellum without evidence of neurological disease in the parental generation places
PRPS1-disease in the differential diagnosis of many adult-onset autosomal-recessive and mitochondrial ataxias where such findings are common and which might be mimicked by
PRPS1-disease. This differential diagnosis includes e.g. OPA3/Type III methylglutaconic aciduria (MIM 606580), OPA1 (MIM 605290) or Wolfram Syndrome (MIM 606201).
Competing interests
Dr. Synofzik received honoraria from Actelion Pharmaceuticals Ltd.
Dr. J. Müller vom Hagen received honoraria from Actelion Pharmaceuticals Ltd.
Dr. Haack reports no disclosures.
Dr. Wilhelm reports no disclosures.
Dr. Lindig received a travel grant by Bayer HealthCare.
Dr. Beck-Wödl received a travel grant by Actelion Pharmaceuticals Ltd.
Dr. Nabuurs reports no disclosures
Dr. van Kuilenburg reports no disclosures.
Dr. de Brouwer reports no disclosures.
Dr. Schöls reports no disclosures.
Authors’ contributions
MS: conceptualization of the study, acquisition of data, analysis of the data, drafting the manuscript. JMvH: acquisition of data, revising the manuscript. TBH: acquisition of data, revising the manuscript. CW: acquisition of data, revising the manuscript. TL: acquisition of data, revising the manuscript. SB-W: acquisition of data, revising the manuscript. SBN: acquisition of data, revising the manuscript. ABPvK: acquisition of data, revising the manuscript. APMdB: acquisition of data, revising the manuscript. LS: supervision of the study, acquisition of data, revising the manuscript. All authors read and approved the final manuscript.